Tevogen Bio (NASDAQ:TVGN – Get Free Report) and Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations for Tevogen Bio and Anavex Life Sciences, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tevogen Bio | 0 | 0 | 1 | 0 | 3.00 |
Anavex Life Sciences | 0 | 0 | 1 | 1 | 3.50 |
Tevogen Bio presently has a consensus target price of $4.20, indicating a potential upside of 479.23%. Anavex Life Sciences has a consensus target price of $40.00, indicating a potential upside of 547.77%. Given Anavex Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Tevogen Bio.
Insider & Institutional Ownership
Profitability
This table compares Tevogen Bio and Anavex Life Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Tevogen Bio | N/A | -273.73% | 229.30% |
Anavex Life Sciences | N/A | -29.04% | -26.85% |
Earnings & Valuation
This table compares Tevogen Bio and Anavex Life Sciences’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tevogen Bio | N/A | N/A | -$70,000.00 | N/A | N/A |
Anavex Life Sciences | N/A | N/A | -$47.51 million | ($0.50) | -12.35 |
Risk & Volatility
Tevogen Bio has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Summary
Anavex Life Sciences beats Tevogen Bio on 6 of the 9 factors compared between the two stocks.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.